<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958997</url>
  </required_header>
  <id_info>
    <org_study_id>Y-003-09</org_study_id>
    <nct_id>NCT00958997</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients</brief_title>
  <official_title>Quantitative PET Imaging of Pancreatic Beta-cell Mass in Healthy and Type 1 Diabetic Patients With 18F-FP-DTBZ (AV-133)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic Islet beta-cells are responsible for synthesizing and secreting appropriate
      amounts of insulin to regulate blood glucose levels. One factor in the development of
      diabetes is the loss of beta-cells. Developing treatments to prevent or restore islet
      beta-cell mass (BCM) in diabetic patients is hampered by a lack of methods for the
      non-invasive imaging of these cells. This study is designed to evaluate a radiolabeled
      compound that binds to the pancreatic islet. The investigators will test the ability of one
      promising imaging compound, 18F-9-fluoropropyl-(+)-dihydrotetrabenazine (18F-FP-DTBZ), to
      measure the amount of pancreatic islet beta-cells in patients with long-standing type-1
      diabetes and in age-weight-matched healthy control subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PET-determined pancreatic islet beta-cell mass</measure>
    <time_frame>150 minutes post-dose of imaging agent</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion response following an acute arginine-stimulus test</measure>
    <time_frame>Six minutes following administration of arginine challange</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Type 1 diabetic subjects</arm_group_label>
    <description>Patients with Type 1 diabetes who have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <description>Age-weight-BMI matched to the subjects with type-1 diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FP-DTBZ (18F-AV-133)</intervention_name>
    <description>The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).</description>
    <arm_group_label>Type 1 diabetic subjects</arm_group_label>
    <arm_group_label>Healthy control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Arginine-hydrochloride</intervention_name>
    <description>A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.</description>
    <arm_group_label>Type 1 diabetic subjects</arm_group_label>
    <arm_group_label>Healthy control subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community Sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with Type 1 diabetes may be enrolled if they meet all of the following
             criteria:

               -  Have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment
                  of physician; diabetes onset younger than age 18, duration &gt;5 years

               -  Have fasting C-Peptide ≤ 0.1 ng/ml

               -  BMI between 18 and 29 kg/m2

               -  Able to tolerate PET and MR imaging

               -  No metal implants

               -  No claustrophobia

          2. Healthy volunteers may be enrolled if they meeting all of the following criteria:

               -  Have no history of Type 1 diabetes

               -  Fasting blood glucose ≤ 100 mg/dL

               -  Negative islet autoantibody testing

               -  BMI between 18 and 29 kg/m2

               -  Able to tolerate PET and MR imaging

               -  No history of previous allergic reactions to drugs

               -  No metal implants

               -  No claustrophobia

        Exclusion Criteria:

          -  Clinically significant renal dysfunction;

          -  Clinically significant liver dysfunction as determined by history, physical
             examination, and standard liver function testing at screening (AST, ALT, Total/Direct
             Bilirubin, Alkaline Phosphatase);

          -  Coagulopathy;

          -  History of allergic reactions to any drug

          -  Current use of any medications except for insulin for Type 1 diabetes

          -  Clinically significant cardiovascular disease or clinically significant abnormalities
             on screening ECG (including but not limited to QTc&gt;450 msec);

          -  Clinically significant psychiatric disease; Clinically significant pulmonary, renal or
             hepatic impairment or cancer, have clinically significant infectious disease,
             including AIDS or HIV infection, or previous positive test for hepatitis B, hepatitis
             C, HIV-1, or HIV-2; subjects will be asked about this. No testing will be performed.

          -  Have a history of alcohol or substance abuse or dependence;

          -  Are women of childbearing potential not refraining from sexual activity or not using
             adequate contraception. Women must not be pregnant (negative serum β-HCG at the time
             of screen) or lactating at screening, and must agree to take appropriate steps not to
             become pregnant during the study and for 30 days following the study.

          -  Currently receiving any investigational medications, or have participated in a trial
             with investigational medications within the last 30 days.

          -  Have received a diagnostic or therapeutic radiopharmaceutical within 7 days prior to
             participation in this study.

          -  Claustrophobia

          -  Metal implants (pace-maker, artificial joints, non-removable body piercings)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary W Cline, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu-Shin Ding, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kitt F Petersen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Carson, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine, PET Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 2006 Aug;33(6):685-94.</citation>
    <PMID>16934687</PMID>
  </reference>
  <reference>
    <citation>Kilbourn MR, Hockley B, Lee L, Hou C, Goswami R, Ponde DE, Kung MP, Kung HF. Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biol. 2007 Apr;34(3):233-7.</citation>
    <PMID>17383572</PMID>
  </reference>
  <reference>
    <citation>Kung MP, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol. 2007 Apr;34(3):239-46.</citation>
    <PMID>17383573</PMID>
  </reference>
  <reference>
    <citation>Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E, Skovronsky D, Kilbourn MR, Kung HF. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med. 2008 Jul;49(7):1171-6. doi: 10.2967/jnumed.108.051680. Epub 2008 Jun 13.</citation>
    <PMID>18552132</PMID>
  </reference>
  <reference>
    <citation>Larsson H, Ahrén B. Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. Diabetologia. 1998 Jul;41(7):772-7.</citation>
    <PMID>9686917</PMID>
  </reference>
  <reference>
    <citation>Rickels MR, Naji A, Teff KL. Acute insulin responses to glucose and arginine as predictors of beta-cell secretory capacity in human islet transplantation. Transplantation. 2007 Nov 27;84(10):1357-60.</citation>
    <PMID>18049122</PMID>
  </reference>
  <reference>
    <citation>Souza F, Simpson N, Raffo A, Saxena C, Maffei A, Hardy M, Kilbourn M, Goland R, Leibel R, Mann JJ, Van Heertum R, Harris PE. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest. 2006 Jun;116(6):1506-13. Epub 2006 May 18.</citation>
    <PMID>16710474</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <last_update_submitted>July 20, 2012</last_update_submitted>
  <last_update_submitted_qc>July 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Gary Cline</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>islet</keyword>
  <keyword>pancreas</keyword>
  <keyword>beta cell mass</keyword>
  <keyword>PET imaging</keyword>
  <keyword>FPDTBZ</keyword>
  <keyword>arginine stimulus test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

